RxDoctor Payments Data

Maria Nunez

Family · Belleville, NJNPI 1750982732

Payments from drug & device makers

$2,349in general payments, 2019–2025

Across 140 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$313
  • Lilly USA, LLC$294
  • Mannkind Corporation$281
  • Amgen$257
  • Sanofi-aventis U.S. LLC$184
  • Insulet Corporation$177
  • plus $843 from 19 others

What the payments were for

  • Food & beverage$2,30798%
  • Gifts$432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,349 in reported general payments places this provider in the 85th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide295$411,213
JardianceEmpagliflozin226$235,478
MounjaroTirzepatide122$177,553
TrulicityDulaglutide126$156,222
FarxigaDapagliflozin Propanediol162$146,158
RybelsusSemaglutide53$88,794
JanuviaSitagliptin Phosphate55$52,664
TradjentaLinagliptin33$37,426
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$25,318
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog59$20,421
Humalog Kwikpen U-100Insulin Lispro74$19,795
Lantus SolostarInsulin Glargine,hum.Rec.Anlog179$19,672
JanumetSitagliptin Phos/Metformin Hcl22$16,782
Tresiba Flextouch U-100Insulin Degludec28$16,090
Tresiba Flextouch U-200Insulin Degludec15$14,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$313$500,008348 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$294$337,980267 claims
Boehringer IngelheimJardiance, Tradjenta$118$272,904259 claims
AstraZenecaFarxiga$66$146,158162 claims
MerckJanuvia, Janumet$15$69,44677 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,692 family providers in New Jersey.

Other family in Belleville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →